Chai Discovery has completed a $130 million Series B financing that the artificial intelligence (AI)-based antibody designer says will help it accelerate its research and product development, as well ...

Nanomedicine and advanced drug delivery platforms are reshaping modern therapeutics by enabling targeted, controlled, and tissue-specific delivery of small ...

The Business in brief section below includes short stories on a fundraising by Medra, which promises AI and machines that can autonomously run experiments from end to end, and a fundraising by ChemLex ...

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t ...

The FDA recently had a meeting to explore regulatory aspects of AI-enabled mental health medical devices. I explore a useful ...

Drug developers increasingly are harnessing AI to optimise clinical trial patient selection and to interpret results to ...

The two investment firms were joined by more than a half dozen other backers. The consortium included OpenAI Group PBC and ...

Artificial intelligence has just exposed a structural flaw in the mpox virus that scientists had not fully appreciated, and ...

Artificial intelligence is no longer a distant threat to the job market, it is already reshaping how specific roles are done ...

NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...

Chai Discovery, an artificial intelligence drug-discovery company backed by OpenAI, has raised $130 million to build a ...

Only 6% of trials for FDA-approved drugs match America's diversity. Analysis reveals how trial location and design choices ...